Pharmacokinetic-Pharmacodynamic Analyses of Dose Selection for Rezafungin Prophylaxis Against Invasive Fungal Infections in Bone Marrow Transplantation

Rezafungin (RZF) is a novel echinocandin in development for prevention of invasive fungal infections caused by Candida, Aspergillus, and Pneumocystis spp. in patients at high risk of infection. RZF has demonstrated in vivo prophylaxis efficacy and low risk of drug-drug interactions. Furthermore, the stability and PK profile of RZF allow for once-weekly dosing.RZF is also in development for treatment of candidemia and invasive candidiasis using a dosing regimen of RZF 400 mg followed by 200 mg once-weekly, which achieved>90% target attainment against Candida.

Source: Biology of Blood and Marrow Transplantation - January 31, 2019 Category: Hematology Authors: Janice (Wes) M. Brown, Elizabeth A Lakota, Shawn Flanagan, Taylor Sandison, Voon Ong, Chris M. Rubino Tags: 537 Source Type: research